Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Dermatitis symbols : TEVJF save search
Eczema Therapeutics Market size is set to grow by USD 5.81 bn from 2024-2028,high prevalence of atopic dermatitis boost the market- Technavio
Published: 2024-04-08 (Crawled : 18:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 2.24%
H: 0.0%
C: -0.8%
AZNCF | News | $136.2 -4.19% 1.7K
|
Health Technology
|
| O: -3.43%
H: 6.21%
C: 6.21%
VTRS | News A | $11.235 -0.13% -0.13% 5.1M
|
Health Technology
|
| O: -0.25%
H: 1.1%
C: -0.17%
NVS | News | $95.12 0.81% -1.18% 2.4M
|
Health Technology
|
| O: -0.05%
H: 0.43%
C: -0.27%
BMY | $49.14 0.43% 0.0% 7.9M
|
Health Technology
|
| O: -0.08%
H: 0.04%
C: -0.35%
BHC | $8.45 -2.76% 0.24% 2.3M
|
Health Technology
|
| O: 0.38%
H: 0.0%
C: -7.27%
ABBV | News | $167.89 0.89% 0.0% 5.6M
|
Health Technology
|
| O: 0.77%
H: 1.63%
C: 0.35%
SNY | News | $47.125 1.78% 1.75% 2.1M
|
Health Technology
|
| O: 0.84%
H: 0.0%
C: 0.0%
AZN | News | $70.12 2.29% 2.24% 4.8M
|
Health Technology
|
| O: 0.18%
H: 0.3%
C: 0.19%
eczema dermatitis set therapeutics market
Global Report on Seborrheic Dermatitis Market Size & Share Worth USD 5 billion, to Record a 11.1% CAGR by 2030 | Seborrheic Dermatitis Industry Trends, Segmentation, Analysis & Forecast by FnF
Published: 2023-02-01 (Crawled : 17:00) - prnewswire.com
LLY | News | $731.33 0.69% 0.0% 2.3M
|
Health Technology
|
| O: -0.4%
H: 0.92%
C: -0.06%
global report dermatitis market
Positive Dupixent® (dupilumab) Phase 3 Data in Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis Published in The Lancet
Published: 2022-09-15 (Crawled : 23:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 0.74%
H: 0.91%
C: -0.74%
SNY | News | $47.125 1.78% 1.75% 2.1M
|
Health Technology
|
| O: -0.52%
H: 0.0%
C: 0.0%
REGN | News | $899.71 0.32% 0.32% 340K
|
Health Technology
|
| O: 0.62%
H: 1.12%
C: 0.01%
dupixent children lancet dermatitis positive
Atopic Dermatitis Drugs Market to Rise at a CAGR of 14.7% during Forecast Period, observes TMR Study
Published: 2022-08-23 (Crawled : 12:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 1.75%
H: 0.0%
C: 0.0%
PFE | News A | $26.26 1.0% -0.08% 36M
|
Health Technology
|
| O: -0.98%
H: 0.21%
C: -0.85%
BHC | $8.45 -2.76% 0.24% 2.3M
|
Health Technology
|
| O: -0.89%
H: 0.54%
C: -5.23%
SNY | News | $47.125 1.78% 1.75% 2.1M
|
Health Technology
|
| O: -0.72%
H: 0.0%
C: 0.0%
dermatitis study market
FDA Approves Dupixent® (dupilumab) as First Biologic Medicine for Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis
Published: 2022-06-07 (Crawled : 21:00) - prnewswire.com
SNY | News | $47.125 1.78% 1.75% 2.1M
|
Health Technology
|
| O: -0.36%
H: 0.0%
C: 0.0%
REGN | News | $899.71 0.32% 0.32% 340K
|
Health Technology
|
| O: 2.14%
H: 0.78%
C: -1.66%
dupixent fda children dermatitis
Press Release: FDA approves Dupixent® (dupilumab) as first biologic medicine for children aged 6 months to 5 years with moderate-to-severe atopic dermatitis
Published: 2022-06-07 (Crawled : 21:00) - globenewswire.com
SNY | News | $47.125 1.78% 1.75% 2.1M
|
Health Technology
|
| O: -0.36%
H: 0.0%
C: 0.0%
REGN | News | $899.71 0.32% 0.32% 340K
|
Health Technology
|
| O: 2.14%
H: 0.78%
C: -1.66%
dupixent fda children dermatitis
FDA Accepts Dupixent® (dupilumab) for Priority Review in Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis
Published: 2022-02-10 (Crawled : 07:00) - prnewswire.com
SNY | News | $47.125 1.78% 1.75% 2.1M
|
Health Technology
|
| O: -0.92%
H: 0.0%
C: 0.0%
REGN | News | $899.71 0.32% 0.32% 340K
|
Health Technology
|
| O: -0.33%
H: 0.0%
C: 0.0%
dupixent fda atopic dermatitis dermatitis derm children fda acceptance
Positive Phase 3 Dupixent® (dupilumab) Data in Children 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis Featured in RAD 2021 Late-breaking Session
Published: 2021-12-13 (Crawled : 08:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 3.01%
H: 0.28%
C: -2.39%
SNY | News | $47.125 1.78% 1.75% 2.1M
|
Health Technology
|
| O: -0.42%
H: 0.0%
C: 0.0%
REGN | News | $899.71 0.32% 0.32% 340K
|
Health Technology
|
| O: -1.54%
H: 0.0%
C: 0.0%
dupixent atopic dermatitis dermatitis positive children phase 3
Gainers vs Losers
| 75% | 25% |
Top 10 Gainers
MTTR | News M | $4.78 174.71% 63.6% 72M
|
AGBA | $2.565 105.2% 51.27% 200M
|
Finance
MLEC | $2.44 74.29% 42.62% 78M
|
n/a
EDBL | News | $6.28 67.02% 40.13% 16M
|
ATGL | $2.91 48.81% 32.8% 180K
|
ZAPP | $0.2175 47.16% 32.05% 16M
|
n/a
ONFO | $0.6075 38.38% 27.74% 7.3M
|
n/a
VIVK | $1.48 38.32% 27.7% 530K
|
Professional, Scientific, and T...
MNTS | $0.5 35.69% 26.3% 4.8M
|
SDIG A | $3.635 35.13% 26.0% 1M
|
Your saved searches
Save your searches and get alerts when important news are released.